EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

OTP, CD44, and Ki-67: A Prognostic Marker Panel for Relapse-Free Survival in Patients with Surgically Resected Pulmonary Carcinoid

Laura Moonen, Jules L Derks, Michael A den Bakker, Lisa M Hillen, Robert Jan van Suylen, Jan H von der Thüsen, Lisa M V Lap, Britney J C A Marijnissen, Ronald A Damhuis, Kim M Smits, Esther C van den Broek, Wieneke A Buikhuisen und 3 weitere

Modern Pathology · 2025-03 · 38 (3) · 100677

DOI: 10.1016/j.modpat.2024.100677 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2025-03. Verfasst von Laura Moonen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, The Netherlands. Hauptthemen laut MEDLINE: Hyaluronan Receptors, Biomarkers, Tumor, Carcinoid Tumor, Lung Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Couch Foundation, KWF Kankerbestrijding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although most patients with pulmonary carcinoid (PC) can be cured by surgery, relapse may occur until 15 years after resection in up to 10% of patients. This is unpredictable at the outset, necessitating extensive follow-up (FU). We sought to determine whether an immunohistochemical marker panel (OTP, CD44, and Ki-67) could better indicate relapse-free survival (RFS) and increase uniformity among pathologists regarding carcinoid classification. To this purpose, all surgically resected PC (2003-2012) were identified in the Dutch cancer/pathology registry, and a matched relapse vs nonrelapse cohort (ratio 1:2, N = 161) was created. Cases were revised by 4 pathologists and additionally for immunohistochemistry (IHC) markers. The marker panel was applied to the complete population-based cohort (N = 536) to investigate the negative predictive value (NPV) of relapse. Median FU was 86.7 months. WHO classification among pathologists revealed poor overall agreement (mitotic count: 0.380, necrosis: 0.476) compared with IHC markers (Ki-67: 0.917, OTP: 0.984, CD44: 0.976). The mean NPV of all pathologists increased from 0.74 (World Health Organization, WHO) to 0.85 (IHC marker panel). IHC risk stratification of the complete cohort, regardless of subtype, showed a statistically significant difference in RFS between patients with high risk (n = 222) and low risk (n = 314), with an NPV of 95.9%. In conclusion, our results support the use of biomarker-driven FU management for patients with PC as the OTP/CD44/KI-67 marker panel can reliably predict which patients will probably not develop relapse over time and may benefit from a more limited postoperative follow-up. Furthermore, IHC marker assessment by pathologists for PC stratification is superior to traditional WHO typing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyaluronan ReceptorsBiomarkers, TumorCarcinoid TumorLung NeoplasmsKi-67 AntigenHumansMaleFemaleMiddle AgedAgedImmunohistochemistryNeoplasm Recurrence, LocalAdultDisease-Free SurvivalPrognosisAged, 80 and overPredictive Value of Tests

Stichwörter der Autor:innen

biomarkerneuroendocrineprognosispulmonary carcinoidrelapse

Substanzen

Hyaluronan ReceptorsBiomarkers, TumorCD44 protein, humanKi-67 Antigen

Autor:innen und Institutionen

  • Department of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Department of Pulmonary Diseases, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Department of Pathology, Maasstad Hospital, Rotterdam, The Netherlands.
  • Department of Pathology, Pathologie-DNA, Location Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.
  • Department of Pathology and Clinical Bioinformatics, Erasmus MC, Rotterdam, The Netherlands.
  • Department of Research, Comprehensive Cancer Association, Utrecht, The Netherlands.

Förderung

  • Cancer Couch Foundation
  • KWF Kankerbestrijding

Zitieren

APA

Moonen, L., Derks, J. L., den Bakker, M. A., Hillen, L. M., van Suylen, R. J., von der Thüsen, J. H., Lap, L. M. V., Marijnissen, B. J. C. A., Damhuis, R. A., Smits, K. M., van den Broek, E. C., Buikhuisen, W. A., PALGA group, Dingemans, A. C., & Speel, E. J. M. (2025). OTP, CD44, and Ki-67: A Prognostic Marker Panel for Relapse-Free Survival in Patients with Surgically Resected Pulmonary Carcinoid. Modern Pathology, 38(3), 100677. https://doi.org/10.1016/j.modpat.2024.100677

Vancouver

Moonen L, Derks JL, den Bakker MA, Hillen LM, van Suylen RJ, von der Thüsen JH, et al. OTP, CD44, and Ki-67: A Prognostic Marker Panel for Relapse-Free Survival in Patients with Surgically Resected Pulmonary Carcinoid. Modern Pathology. 2025;38(3):100677. doi:10.1016/j.modpat.2024.100677

BibTeX
@article{Moonen2025,
  author = {Moonen, Laura and Derks, Jules L and den Bakker, Michael A and Hillen, Lisa M and van Suylen, Robert Jan and von der Thüsen, Jan H and Lap, Lisa M V and Marijnissen, Britney J C A and Damhuis, Ronald A and Smits, Kim M and van den Broek, Esther C and Buikhuisen, Wieneke A and PALGA group, PALGA group and Dingemans, Anne-Marie C and Speel, Ernst Jan M},
  title = {OTP, CD44, and Ki-67: A Prognostic Marker Panel for Relapse-Free Survival in Patients with Surgically Resected Pulmonary Carcinoid},
  journal = {Modern Pathology},
  year = {2025},
  volume = {38},
  number = {3},
  pages = {100677},
  doi = {10.1016/j.modpat.2024.100677}
}
Kostenlos starten →